3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Conditions
Urologic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Adenoid Cystic
1
Interventions
pembrolizumab
7
Nivolumab
3
poly ICLC
2
durvalumab
2
Rituximab
2
Gemcitabine
2
Capecitabine
2
utomilumab
1
tremelimumab
1
tanespimycin
1
mirabegron
1
entinostat
1
ciforadenant
1
cemiplimab
1
Vorinostat
1
Thalidomide
1
Specimen Handling
1
SUB1 protein, human
1
SRA737
1
Ritonavir
1
Radiotherapy
1
Radiation
1
Polymerase Chain Reaction
1
Paclitaxel
1
Nicotine
1
Microarray Analysis
1
Magnetic Resonance Spectroscopy
1
Magnetic Resonance Imaging
1
Injections, Subcutaneous
1
Indinavir
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
GSK-3326595
×
Lymphoid
×
Clear all
NCT02783300
2025-03-10
Meteor 1
GlaxoSmithKline
Phase 1
Completed
297 enrolled
76 charts